de J Guerrero-García José, Rojas-Mayorquín Argelia E, Valle Yeminia, Padilla-Gutiérrez Jorge R, Castañeda-Moreno Víctor A, Mireles-Ramírez Mario A, Muñoz-Valle José F, Ortuño-Sahagún Daniel
Instituto de Investigación en Ciencias Biomédicas (IICB), CUCS, Universidad de Guadalajara, Jalisco, Mexico; Unidad Médica de Alta Especialidad (UMAE), Hospital de Pediatría (HP), Centro Médico Nacional de Occidente (CMNO), IMSS, Mexico.
Departamento de Ciencias Ambientales, Instituto de Neurociencias, CUCBA, Universidad de Guadalajara, Jalisco, Mexico.
Immunobiology. 2018 Jan;223(1):135-141. doi: 10.1016/j.imbio.2017.10.001. Epub 2017 Oct 5.
The CD40/CD40L system is a binding key for co-stimulation of immune cells. Soluble form of CD40L has been widely studied as marker of inflammatory and autoimmune diseases. Here we analyze serum concentrations of sCD40L, as well as 14 cytokines, in patients with Multiple Sclerosis (MS) treated with Glatiramer acetate or Interferon beta. In the healthy control group, we found in serum a highly positive correlation between sCD40L and Interleukin (IL)-31, an anti-inflammatory Th2 cytokine. Additionally, an important reduction in IL-31 and sCD40L serum levels, as well as a significant reduction in CD40 mRNA expression and complete depletion of CD40L mRNA, detected from peripheral blood cells, was found in treated patients with MS. Therefore, sCD40L and IL-31 must be taken into account as possible prognostic markers when analyzing the disease progress of MS in order to provide more personalized treatment.
CD40/CD40L系统是免疫细胞共刺激的关键结合因子。可溶性CD40L形式已作为炎症和自身免疫性疾病的标志物被广泛研究。在此，我们分析了接受醋酸格拉替雷或β-干扰素治疗的多发性硬化症（MS）患者血清中可溶性CD40L（sCD40L）以及14种细胞因子的浓度。在健康对照组中，我们发现血清中sCD40L与白细胞介素（IL）-31（一种抗炎性Th2细胞因子）之间存在高度正相关。此外，在接受治疗的MS患者中，发现IL-31和sCD40L血清水平显著降低，同时从外周血细胞检测到CD40 mRNA表达明显降低以及CD40L mRNA完全缺失。因此，在分析MS疾病进展时，sCD40L和IL-31必须作为可能的预后标志物加以考虑，以便提供更个性化的治疗。
